Consano Bio Gains FDA Fast Track for C-1101
BURLINGTON, Mass., August 18, 2026 Consano Bio, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted...
FDA IND
Advertisement
Trace Biosciences and Axogen Advance Nerve Trace Technology
PORTLAND, Ore., July 29, 2026 Trace Biosciences, Inc. has secured a strategic investment from Axogen, Inc. to accelerate clinical...
Siren Biotechnology Secures $8M CIRM Grant for SRN-101 Trial
SAN FRANCISCO, Calif., June 26, 2026 Siren Biotechnology has been awarded an $8 million non-dilutive CLIN2 grant from the...
Ascletis Receives FDA IND Clearance for ASC35 Obesity Trial
HONG KONG, June 23, 2026 Ascletis Pharma Inc. announced that the U.S. Food and Drug Administration (FDA) has granted...
Phanes Completes Phase 2 Enrollment for Spevatamig in PDAC
SAN DIEGO, California, June 22, 2026 Phanes Therapeutics has announced the successful completion of patient enrollment in its Phase...
Advertisements
Hamlet BioPharma Expands Alpha1H Trial for Bladder Cancer
LUND, Sweden, June 22, 2026 Hamlet BioPharma AB has announced a significant expansion of its U.S. clinical development program...
DemeRx Gains FDA IND Clearance for DMX-1001 in AUD
Miami, Florida, USA – April 23, 2026 DemeRx announced that the U.S. Food and Drug Administration (FDA) has accepted...
Mabwell Advances SST001 PET Tracer to Phase I Trial
SHANGHAI, CHINA, April 14, 2026 Mabwell (688062.SH) has announced that SST001 (18F-FD4), an innovative α-synuclein-targeted PET tracer developed by...
Enveric Biosciences Gains U.S. Patent for EVM301
CAMBRIDGE, Mass., March 31, 2026 Enveric Biosciences has strengthened its position in the rapidly evolving neuropsychiatric drug development space...
Gyre Therapeutics Advances Fibrosis-First Pipeline with Strong Q3 Growth and Regulatory Momentum
Dateline — San Diego, California, November 7, 2025:Gyre Therapeutics, Inc. (NASDAQ: GYRE) reported Q3 2025 financial results and a...
Advertisement
